Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation (loxapine)
A Randomized Double-blind Multicenter Double-dummy Non-inferiority Trial of Inhaled Loxapine and Intramuscular Haloperidol + Lorazepam for the Reduction of Agitation
Sponsor: Mount Sinai Hospital, Chicago
Terminated
Sponsor Withdrawal
Other Agitation,Psychomotor trials with similar outcome
Listed as NCT03110900, this PHASE4 trial focuses on Agitation,Psychomotor and Haloperidol Causing Adverse Effects in Therapeutic Use and remains terminated or withdrawn. Sponsored by Mount Sinai Hospital, Chicago, it has been updated 8 times since 2017, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE4
-
Jul 2018 — Jan 2021 [monthly]
Terminated PHASE4
-
Jun 2018 — Jul 2018 [monthly]
Terminated PHASE4
▶ Show 3 earlier versions
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE4
Status: Recruiting → Terminated
-
Nov 2017 — May 2018 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
May 2017 — Nov 2017 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Mount Sinai Hospital, Chicago
- University of Arkansas
For direct contact, visit the study record on ClinicalTrials.gov .